Immunity to tumor-associated antigens in vasectomized men

D. J. Anderson, N. J. Alexander, D. L. Fulgham, Arthur Vandenbark, D. R. Burger

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Leukocytes from 49 vasectomized and 57 age-matched nonvasectomized men were tested in the leukocyte adherence inhibition (LAI) assay for reactivity to sperm and various 3-M KCl human tumor extracts. Forty-four percent of the vasectomized men and 15% of the control group were reactive to the sperm antigen preparation (P ≤0.03). Similarly, a significantly higher percentage of vasectomized men responded to 3 of 5 tumor extracts tested: melanoma I (34.7 vs 15.8%, P ≤0.04), squamous cell carcinoma (48.8 vs, 26.0%, P ≤0.04), and breast carcinoma (19.5 vs. 4%, P ≤0.04). Thirty percent of vasectomized versus 4% of the control group responded to more than two tumor antigens (P ≤0.03). The degree of LAI reactivity to each tumor extract was highly correlated with degree of antisperm LAI reactivity, and the degree of LAI responsiveness to one of the melanoma extracts was significantly correlated with antisperm antibody titer as measured by the sperm-immobilization assay. Furthermore, nonresponsive leukocytes from the control population converted to tumor antigen-responsive when incubated with sera from vasectomized LAI-positive men. Data from this study indicated that a large percentage of vasectomized men with sperm immunity were responsive to tumor-associated antigens in the LAI test and that antisperm antibodies or other serum factors played a role in this response. These results and the evidence that most tumor antigen-responsive cancer patients also have serum antibodies that reacted with sperm suggested that vasectomized men and cancer patients frequently responded to immunologically cross-reactive antigenic determinants present on both sperm and tumor cells.

Original languageEnglish (US)
Pages (from-to)551-555
Number of pages5
JournalJournal of the National Cancer Institute
Volume69
Issue number3
StatePublished - 1982
Externally publishedYes

Fingerprint

Neoplasm Antigens
Immunity
Leukocytes
Spermatozoa
Neoplasms
Antibodies
Melanoma
Leukocyte Adherence Inhibition Test
Serum
Control Groups
Immobilization
Epitopes
Squamous Cell Carcinoma
Breast Neoplasms
Antigens
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anderson, D. J., Alexander, N. J., Fulgham, D. L., Vandenbark, A., & Burger, D. R. (1982). Immunity to tumor-associated antigens in vasectomized men. Journal of the National Cancer Institute, 69(3), 551-555.

Immunity to tumor-associated antigens in vasectomized men. / Anderson, D. J.; Alexander, N. J.; Fulgham, D. L.; Vandenbark, Arthur; Burger, D. R.

In: Journal of the National Cancer Institute, Vol. 69, No. 3, 1982, p. 551-555.

Research output: Contribution to journalArticle

Anderson, DJ, Alexander, NJ, Fulgham, DL, Vandenbark, A & Burger, DR 1982, 'Immunity to tumor-associated antigens in vasectomized men', Journal of the National Cancer Institute, vol. 69, no. 3, pp. 551-555.
Anderson, D. J. ; Alexander, N. J. ; Fulgham, D. L. ; Vandenbark, Arthur ; Burger, D. R. / Immunity to tumor-associated antigens in vasectomized men. In: Journal of the National Cancer Institute. 1982 ; Vol. 69, No. 3. pp. 551-555.
@article{5c9d083e716448a9bbbae026abb1f342,
title = "Immunity to tumor-associated antigens in vasectomized men",
abstract = "Leukocytes from 49 vasectomized and 57 age-matched nonvasectomized men were tested in the leukocyte adherence inhibition (LAI) assay for reactivity to sperm and various 3-M KCl human tumor extracts. Forty-four percent of the vasectomized men and 15{\%} of the control group were reactive to the sperm antigen preparation (P ≤0.03). Similarly, a significantly higher percentage of vasectomized men responded to 3 of 5 tumor extracts tested: melanoma I (34.7 vs 15.8{\%}, P ≤0.04), squamous cell carcinoma (48.8 vs, 26.0{\%}, P ≤0.04), and breast carcinoma (19.5 vs. 4{\%}, P ≤0.04). Thirty percent of vasectomized versus 4{\%} of the control group responded to more than two tumor antigens (P ≤0.03). The degree of LAI reactivity to each tumor extract was highly correlated with degree of antisperm LAI reactivity, and the degree of LAI responsiveness to one of the melanoma extracts was significantly correlated with antisperm antibody titer as measured by the sperm-immobilization assay. Furthermore, nonresponsive leukocytes from the control population converted to tumor antigen-responsive when incubated with sera from vasectomized LAI-positive men. Data from this study indicated that a large percentage of vasectomized men with sperm immunity were responsive to tumor-associated antigens in the LAI test and that antisperm antibodies or other serum factors played a role in this response. These results and the evidence that most tumor antigen-responsive cancer patients also have serum antibodies that reacted with sperm suggested that vasectomized men and cancer patients frequently responded to immunologically cross-reactive antigenic determinants present on both sperm and tumor cells.",
author = "Anderson, {D. J.} and Alexander, {N. J.} and Fulgham, {D. L.} and Arthur Vandenbark and Burger, {D. R.}",
year = "1982",
language = "English (US)",
volume = "69",
pages = "551--555",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Immunity to tumor-associated antigens in vasectomized men

AU - Anderson, D. J.

AU - Alexander, N. J.

AU - Fulgham, D. L.

AU - Vandenbark, Arthur

AU - Burger, D. R.

PY - 1982

Y1 - 1982

N2 - Leukocytes from 49 vasectomized and 57 age-matched nonvasectomized men were tested in the leukocyte adherence inhibition (LAI) assay for reactivity to sperm and various 3-M KCl human tumor extracts. Forty-four percent of the vasectomized men and 15% of the control group were reactive to the sperm antigen preparation (P ≤0.03). Similarly, a significantly higher percentage of vasectomized men responded to 3 of 5 tumor extracts tested: melanoma I (34.7 vs 15.8%, P ≤0.04), squamous cell carcinoma (48.8 vs, 26.0%, P ≤0.04), and breast carcinoma (19.5 vs. 4%, P ≤0.04). Thirty percent of vasectomized versus 4% of the control group responded to more than two tumor antigens (P ≤0.03). The degree of LAI reactivity to each tumor extract was highly correlated with degree of antisperm LAI reactivity, and the degree of LAI responsiveness to one of the melanoma extracts was significantly correlated with antisperm antibody titer as measured by the sperm-immobilization assay. Furthermore, nonresponsive leukocytes from the control population converted to tumor antigen-responsive when incubated with sera from vasectomized LAI-positive men. Data from this study indicated that a large percentage of vasectomized men with sperm immunity were responsive to tumor-associated antigens in the LAI test and that antisperm antibodies or other serum factors played a role in this response. These results and the evidence that most tumor antigen-responsive cancer patients also have serum antibodies that reacted with sperm suggested that vasectomized men and cancer patients frequently responded to immunologically cross-reactive antigenic determinants present on both sperm and tumor cells.

AB - Leukocytes from 49 vasectomized and 57 age-matched nonvasectomized men were tested in the leukocyte adherence inhibition (LAI) assay for reactivity to sperm and various 3-M KCl human tumor extracts. Forty-four percent of the vasectomized men and 15% of the control group were reactive to the sperm antigen preparation (P ≤0.03). Similarly, a significantly higher percentage of vasectomized men responded to 3 of 5 tumor extracts tested: melanoma I (34.7 vs 15.8%, P ≤0.04), squamous cell carcinoma (48.8 vs, 26.0%, P ≤0.04), and breast carcinoma (19.5 vs. 4%, P ≤0.04). Thirty percent of vasectomized versus 4% of the control group responded to more than two tumor antigens (P ≤0.03). The degree of LAI reactivity to each tumor extract was highly correlated with degree of antisperm LAI reactivity, and the degree of LAI responsiveness to one of the melanoma extracts was significantly correlated with antisperm antibody titer as measured by the sperm-immobilization assay. Furthermore, nonresponsive leukocytes from the control population converted to tumor antigen-responsive when incubated with sera from vasectomized LAI-positive men. Data from this study indicated that a large percentage of vasectomized men with sperm immunity were responsive to tumor-associated antigens in the LAI test and that antisperm antibodies or other serum factors played a role in this response. These results and the evidence that most tumor antigen-responsive cancer patients also have serum antibodies that reacted with sperm suggested that vasectomized men and cancer patients frequently responded to immunologically cross-reactive antigenic determinants present on both sperm and tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=0019957260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019957260&partnerID=8YFLogxK

M3 - Article

C2 - 6180209

AN - SCOPUS:0019957260

VL - 69

SP - 551

EP - 555

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -